Nephrology
For the development of this project the therapeutic potential of secretomes from specific cell types is utilized to chronic kidney disease in humans. The secretomes are packaged within exosomes or synthetic exosomes to deliver their therapeutic action at the site of demand.
Chronic kidney disease is a progressive disease that results from gradual loss of kidney functionality over time and can lead to complete kidney failure. It is a condition caused by many factors (genetic, lifestyle, underlying diseases) and has no cure.
Mesenchymal stem cells (MSCs) can be an important tool for treatment of kidney disease. Their action is mediated primarily through paracrine effects: following systemic administration, mesenchymal stem cells migrate to damaged kidney sites, where they produce an array of anti-inflammatory cytokines, chemokines and growth factors. These secreted biomolecules can prevent further tissue injury and degeneration, most probably through activation of resident renal stem/progenitor cells, that in turn take place in a cascade of events that eventually triggers regeneration of diseased tissue.
The application of stem cells plays a crucial role in therapy delivery, as their action has a transient effect if left unmanipulated, since their interaction with the tissue is naturally qualitatively and quantitatively
limited. Ideally, appropriate homing of the cells is required, so that they interact with the kidney for longer periods of time, so that their paracrine effect is exerted efficiently.
Theracell is in the process of developing novel therapies for the treatment of Chronic Kidney Disease. These therapies use Adipose-Derived Stem Cells (ADSC), appropriately targeted within the organism by the use of nanoparticles.
27 Evrota Street
145 64 Kifissia
GREECE
1 Apollonos St. Parodos, Industrial Zone
194 00 - Koropi
GREECE
© Copyright – Theracell | Developed by ADS Solutions
